Sign in →

Test Code PEE Porphyrins Evaluation, Whole Blood

Additional Codes

Hospital Order Code
Lab2608   MISMGO

 

Reporting Name

Porphyrins Evaluation, WB

Useful For

Establishing a biochemical diagnosis of erythropoietic protoporphyria and X-linked dominant protoporphyria

Reflex Tests

Test ID Reporting Name Available Separately Always Performed
PPFE Protoporphyrins, Fractionation, WB Yes No

Method Name

Spectrofluorometric

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type

Whole blood


Ordering Guidance


This is the preferred test for assessment for protoporphyria. The preferred test for assessing lead toxicity in children is blood lead. For more information see PBDV / Lead, Venous, with Demographics, Blood or PBDC / Lead, Capillary, with Demographics, Blood. The preferred screening test for suspicion of a hepatic porphyria is urine porphyrins. For more information see PQNRU / Porphyrins, Quantitative, Random, Urine.



Necessary Information


Include a list of medications the patient is currently taking.



Specimen Required


All porphyrin tests on whole blood can be performed on 1 collection tube.

 

Patient Preparation: Patient must not consume any alcohol for 24 hours before specimen collection.

Container/Tube:

Preferred: Green top (sodium heparin)

Acceptable: Lavender top (EDTA), dark blue top (metal free heparin), royal blue top (metal free EDTA), green top (lithium heparin)

Specimen Volume: 4 mL

Collection Instructions: Immediately place specimen on wet ice.


Specimen Minimum Volume

3 mL

Specimen Stability Information

Specimen Type Temperature Time
Whole blood Refrigerated 7 days

Reject Due To

Gross hemolysis Reject

Day(s) Performed

Monday through Friday

CPT Code Information

84311

82542-if appropriate

LOINC Code Information

Test ID Test Order Name Order LOINC Value
PEE Porphyrins Evaluation, WB 2814-2

 

Result ID Test Result Name Result LOINC Value
88886 Total Porphyrins, WB 2814-2
29356 Interpretation 59462-2

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

Report Available

3 to 5 days